-
Price Momentum
NVAX is trading in the middle of its 52-week range and above its 200-day simple moving average.
-
Price change
The price of NVAX shares has increased $0.29 since the market last closed. This is a 3.48% rise.
-
Last closed at $8.62.
The stock has since dropped $0.02 in pre-market trading.
Key terms
About NVAX
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
-
Market cap: $1.40B
A market capitalization between $300 million and $2 billion places NVAX in the small capitalization category.
Key terms
Smart score
Latest NVAX news
NVAX Financials
-
Total revenue: $682.16M (1Y), $239.24M (Q2)
Total Revenue decreased 30.65% since last year and decreased 64.11% since last quarter.
-
Net income: -$187.50M (1Y), $106.51M (Q2)
Net Income increased 65.6% since last year and decreased 79.46% since last quarter.
-
Earnings per share: -$1.23 (1Y), $0.60 (Q2)
EPS increased 77.22% since last year and decreased 79.42% since last quarter.
Key terms
NVAX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NVAX Competitors
-
How competitors are chosen
NVAX's competitors are included in the Health Technology sector and Biotechnology group
-
Market cap: $1.40B
A market capitalization between $300 million and $2 billion places NVAX in the small capitalization category.
Key terms
Latest investing news
-
Silver prices hit record high as investors rush into safe havens
-
Jamie Dimon announces massive $10 billion bet on US national security: ‘We need to act now’
-
Dow tumbles nearly 900 points after Trump reignites trade war between the world’s two largest economies
-
Jamie Dimon is worried about a stock market correction